

GLOBAL MARKETS FOR ASTHMA AND COPD DRUGS



PHM059B
August 2012

Peggy Lehr
Project Analyst

ISBN: 0-89336-063-5

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports: carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	1
STUDY GOALS AND OBJECTIVES	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	1
METHODOLOGY	2
INTENDED AUDIENCE	2
INFORMATION SOURCES	2
ANALYST CREDENTIALS	3
RELATED BCC REPORTS	3
BCC ONLINE SERVICES	3
DISCLAIMER	3
CHAPTER 2 SUMMARY	5
SUMMARY TABLE GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, THROUGH 2017 (\$ MILLIONS)	6
SUMMARY FIGURE GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY REGION, 2012 AND 2017 (%)	6
CHAPTER 3 OVERVIEW	9
PULMONARY DRUG DELIVERY	9
PULMONARY CONDITIONS AND THERAPIES	9
RESPIRATORY SYSTEM	9
LUNG	11
Particle Size, Toxicity and Drug Deposition	11
Systemic and Local Therapy	12
Pulmonary Drug Delivery-Devices	12
Device Characteristics	12
Manufacturing Techniques	14
ASTHMA	16
Symptoms of Asthma	17
Global Prevalence	17
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	17
Symptoms of COPD	17
Medication Treatment	18
Types of Medication Treatments	18
Classification of Asthma and COPD Medications	18
Bronchodilators	18
Quick-acting Bronchodilators	18
Two Classes of Long-Term Bronchodilators	19
Anti-inflammatory Drugs	19
Combination Inhaled Corticosteroids and Long-acting Beta-2 Agonists (ICS/LABA)	19
Advantages of ICS/LABA	20
TABLE 1 MARKETED ASTHMA AND COPD DRUG CLASSES	20
Drug Delivery Methods	20
Inhaled Drugs	21
Metered-dose Inhaler	21

TOPIC	PAGE NO.
Pressurized MDI Devices	21
Types of Metered-dose Inhalers	21
Breath-activated Inhalers	21
Types of Breath-activated Inhalers	22
Dry Powder Inhalers	22
Disadvantages of DPI	22
Types of DPI Inhalers	22
Nebulizers	22
Usage	23
Types of Nebulized Drugs	23
Oral and Injectable Drugs	23
Oral Drug Types	23
Injectable Drug Types	23
ADVANTAGES/DISADVANTAGES OF DRUG DELIVERY METHODS	23
DRUG DEVELOPMENT PROCESS	24
DEVELOPMENT OF DISEASE-MODIFYING DRUGS	24
New Drug Targets	24
TECHNICAL ASPECTS IN THE DEVELOPMENT OF INHALED DRUGS	25
INTELLECTUAL PROPERTY RIGHTS	25
DRUG DEVELOPMENT	25
COMPLEX REGULATORY DRUG APPROVAL PROCESS	26
Approval Times	26
REGULATORY ISSUES	26
REMOVAL OF CFC-PROPELLED INHALERS	26
FDA DRUG SAFETY WARNINGS	27
INDUSTRY PLAYERS	27
TIERS OF COMPETITION	27
MAJOR DRUG MANUFACTURERS	28
GlaxoSmithKline	28
Merck	28
Boehringer Ingelheim	28
<i>TABLE 2 NET REVENUES FOR TOP SIX ASTHMA/COPD PRODUCT MANUFACTURERS, WITH PRODUCT(S), 2010 AND 2011 (\$ MILLIONS)</i>	29
SPECIALTY PHARMACEUTICAL COMPANIES	29
Teva Pharmaceutical	29
Chiesi Farmaceutici	29
Sunovion/Sepracor	30
<i>TABLE 3 NET REVENUES FOR TOP SPECIALTY ASTHMA/COPD MANUFACTURERS WITH PRODUCT(S), 2010 AND 2011 (\$ MILLIONS)</i>	30
SMALLER COMPANIES	30
<i>TABLE 4 NET REVENUES FOR SMALLER ASTHMA/COPD PRODUCT MANUFACTURER, WITH PRODUCT, 2010 AND 2011 (\$ MILLIONS)</i>	30
ACQUISITIONS AND MERGERS	31
<i>TABLE 5 ACQUISITIONS AND MERGERS IN THE ASTHMA AND COPD MARKET, JANUARY 2008 TO JUNE 2012 (\$ MILLIONS)</i>	31
COMPETITIVE FACTORS	31
SIX COMPETITIVE FACTORS	31
Delivery Mode and Convenience	32

TOPIC	PAGE NO.
Product Efficacy and Dosage Frequency	32
Safety	33
Combination Drugs	33
Drug Pricing	33
Sales and Marketing	33
SIGNIFICANT TRENDS	34
GLOBAL AGING POPULATION LEADS TO INCREASING ASTHMA AND COPD PREVALENCE	34
NEW DRUG LAUNCHES OFFER ENHANCED TREATMENT OPTIONS	34
PATENT EXPIRATIONS OF MAJOR DRUGS AND GENERIC DRUG LAUNCHES WILL CHANGE THE MARKET	34
<i>TABLE 6 MAJOR ASTHMA/COPD DRUGS THAT LOSE PATENT PROTECTION BETWEEN 2008 AND 2024</i>	35
MARKET CHALLENGES	36
TECHNICAL- AND MARKET-SPECIFIC EXPERTISE REQUIRED TO COMPETE IN THIS THERAPEUTIC AREA	36
FILLING UNMET NEEDS	36
DISEASE-MODIFYING DRUGS	36
SUPERIOR EFFICACY DRUGS	37
IMPROVED SAFETY PROFILE DRUGS	37
IMPROVED DRUG DELIVERY MODALITIES	37
IMPROVED QUALITY OF LIFE FOR PATIENTS	37
REGIONAL ANALYSIS	38
THE AMERICAS	38
Demographic Findings	38
Asthma and Children in the Americas	38
Loss of Patent Protection	38
Product Usage	39
EMRA	39
Demographic Findings	39
Asthma and Children	39
Product Usage	39
ASIA	40
Demographic Findings	40
Asthma and Children in Asia	40
Product Usage	40
CHAPTER 4 DISEASE OVERVIEW	42
SYMPTOM COMPARISONS	42
<i>TABLE 7 ASTHMA AND COPD SYMPTOM COMPARISONS</i>	42
ASTHMA OVERVIEW	42
ASTHMA IN CHILDREN	42
ASTHMA IN ADULTS	43
GLOBAL ECONOMIC BURDEN OF ASTHMA	43
CLASSIFICATION OF ASTHMA	43
<i>TABLE 8 CLASSIFICATION OF ASTHMA, BY SYMPTOMS</i>	44
CAUSES AND RISK FACTORS	44
DIAGNOSIS	44

TOPIC	PAGE NO.
Diagnostic Tests	45
Spirometry	45
Peak Flow Test	45
Methacholine Bronchial Challenge Test	45
Nitric Oxide Test	45
Skin or Blood Test	46
DRUG CLASSES APPROVED IN THE TREATMENT OF ASTHMA AND COPD	46
<i>TABLE 9 ASTHMA AND COPD DRUG CLASSES</i>	46
Bronchodilators	46
Anti-inflammatory drugs	46
Combination Therapies of Bronchodilators and Anti-inflammatory Drugs	47
MEDICATION TREATMENT ALGORITHMS	47
First Line Therapy	47
Second Line Therapy	47
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	48
CLASSIFICATION OF COPD	48
<i>TABLE 10 CLASSIFICATION OF COPD AND ASTHMA</i>	49
CAUSES AND RISK FACTORS	49
DIAGNOSIS	49
COPD TREATMENT METHODS	49
Vaccine	49
Rehabilitation	50
Oxygen Therapy	50
Surgery	50
Medication Treatments	50
Drug Selection	51
REGIONAL STATISTICS	51
ACCESS TO CARE	51
AVAILABILITY OF TREATMENTS	52
NORTH AMERICA	52
Asthma in the U.S.	52
Adults and Asthma in the U.S.	52
Asthma in Canada	53
Asthma in Central America	53
Asthma in the Caribbean	53
ASTHMA IN SOUTH AMERICA	54
<i>TABLE 11 PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN THE AMERICAS (%)</i>	54
COPD IN THE U.S.	55
EMRA	55
Asthma in EMRA	55
Scandinavian/Baltic countries	55
Asthma in the UK and Ireland	55
Asthma in Western Europe	56
Asthma in Eastern Europe	56
Asthma in Russia	56
Asthma in the Middle East	57

TOPIC	PAGE NO.
<i>TABLE 12 PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN THE EMRA (%)</i>	57
COPD in EMRA	58
COPD in Russia	58
ASIA	58
Asthma in Asia	58
Asthma in Central Asia	58
Asthma in Southern Asia	59
Asthma in China/Taiwan/Mongolia	59
Asthma in Northeast Asia	59
Asthma in Southeast Asia	60
Asthma in Oceania	60
<i>TABLE 13 PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN ASIA</i>	61
COPD in Asia	61
CHAPTER 5 MARKETS BY DRUG CLASS	63
<i>TABLE 14 PROJECTED GLOBAL MARKET FOR ASTHMA AND COPD DRUG, BY DRUG CLASS, THROUGH 2017 (\$ MILLIONS)</i>	63
BRONCHODILATORS	63
MARKET REVENUES AND FORECAST	63
<i>FIGURE 1 GLOBAL BRONCHODILATOR MARKET, BY TYPE, 2012 AND 2017 (%)</i>	64
<i>TABLE 15 PROJECTED GLOBAL MARKET FOR BRONCHODILATORS, THROUGH 2017 (\$ MILLIONS)</i>	65
MANUFACTURERS' MARKET SHARE FOR BRONCHODILATORS	65
<i>FIGURE 2 GLOBAL MARKET SHARE FOR BRONCHODILATORS BY COMPANY, 2011 (%)</i>	65
SHORT-ACTING BETA-2 AGONISTS	66
<i>TABLE 16 SHORT-ACTING BETA-2 AGONISTS, WITH APPROVAL AND PATENT EXPIRY DATES, 2011</i>	67
Market Revenues and Forecast	67
Advantages/Disadvantages	68
<i>TABLE 17 PROJECTED MARKET FOR SHORT-ACTING BETA-2 AGONIST BRONCHODILATORS, THROUGH 2017 (\$ MILLIONS)</i>	68
LONG-ACTING BETA-2 AGONISTS	68
<i>TABLE 18 LONG-ACTING BETA-2 AGONISTS, 2011</i>	69
Market Revenues and Forecast	69
<i>TABLE 19 PROJECTED GLOBAL MARKET FOR LABA PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	70
<i>FIGURE 3 MARKET SHARE FOR LABA BRONCHODILATORS BY COMPANY, 2011 (%)</i>	70
ANTICHOLINERGICS AND COMBINATION ANTICHOLINERGICS/SABA	71
<i>TABLE 20 ANTICHOLINERGICS AND COMBINATION ANTICHOLINERGICS/SABA BY MANUFACTURER, 2011</i>	71
Market Revenues and Forecast	71
<i>TABLE 21 PROJECTED GLOBAL MARKET FOR ANTICHOLINERGICS, THROUGH 2017 (\$ MILLIONS)</i>	72
ANTI-INFLAMMATORY DRUGS	72
Market Revenues and Forecast	72
<i>FIGURE 4 MARKET SHARE OF ANTI-INFLAMMATORY DRUGS BY TYPE, 2012 AND 2017 (%)</i>	72
<i>TABLE 22 PROJECTED GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	74

TOPIC	PAGE NO.
Inhaled Corticosteroids	74
<i>TABLE 23 INHALED CORTICOSTEROIDS, 2011</i>	75
<i>FIGURE 5 MARKET SHARE OF LEADING MANUFACTURERS OF INHALED CORTICOSTEROIDS, 2011 (%)</i>	76
Competition in the ICS market	76
<i>TABLE 24 PROJECTED GLOBAL MARKET FOR INHALED CORTICOSTEROIDS, THROUGH 2017 (\$ MILLIONS)</i>	77
LEUKOTRIENE MODIFIERS	77
<i>TABLE 25 LEUKOTRIENE MODIFIERS, 2011</i>	77
Market Revenues and Forecast	78
<i>TABLE 26 PROJECTED GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, THROUGH 2017 (\$ MILLIONS)</i>	78
<i>FIGURE 6 GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, BY MANUFACTURER, 2012 AND 2017 (%)</i>	79
PDE-4 INHIBITORS	80
<i>TABLE 27 PROJECTED GLOBAL MARKET FOR PDE-4 DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	80
BIOLOGICAL DRUGS	80
MARKET REVENUES AND FORECAST	80
Increasing Market for Biological Drugs to Treat Asthma	80
<i>TABLE 28 PROJECTED GLOBAL MARKET FOR ASTHMA BIOLOGICAL DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	81
COMBINATION ICS/LABA DRUGS	81
<i>TABLE 29 COMBINATION ICS/LABA DRUGS, 2011</i>	81
MARKET REVENUES AND FORECAST	82
<i>TABLE 30 PROJECTED GLOBAL MARKET FOR COMBINATION ICS/LABA DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	82
<i>FIGURE 7 MARKET SHARE OF MANUFACTURERS OF ICS/LABA, 2011 (%)</i>	83
Market Dynamics	83
Flutiform	84
Dulera	84
Relovair	84
REGIONAL ANALYSIS	84
<i>TABLE 31 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	85
The Americas	85
<i>TABLE 32 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE AMERICAS REGION, THROUGH 2017 (\$ MILLIONS)</i>	85
Projected Use of Asthma/COPD Drugs, by Americas' Regions	85
<i>TABLE 33 PROJECTED USE OF ASTHMA/COPD DRUGS IN THE AMERICAS' REGION, THROUGH 2017 (\$ MILLIONS)</i>	86
<i>FIGURE 8 MARKET PERCENT OF ASTHMA/COPD DRUGS IN THE AMERICAS REGION, 2012 AND 2017 (%)</i>	86
EMRA	87
<i>TABLE 34 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE EMRA, THROUGH 2017 (\$ MILLIONS)</i>	87
<i>TABLE 35 PROJECTED USE OF ASTHMA/COPD DRUGS IN THE EMRA REGION, THROUGH 2017 (\$ MILLIONS)</i>	87
<i>FIGURE 9 MARKET PERCENT OF ASTHMA/COPD DRUGS IN THE EMRA, 2012 AND 2017 (%)</i>	88
Asia	89

TOPIC	PAGE NO.
<i>TABLE 36 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE ASIAN REGION, THROUGH 2017 (\$ MILLIONS)</i>	89
<i>TABLE 37 PROJECTED USE OF ASTHMA/COPD DRUGS, BY REGION IN ASIA, THROUGH 2017 (\$ MILLIONS)</i>	89
<i>FIGURE 10 MARKET PERCENTAGE OF ASTHMA/COPD DRUGS, BY REGION IN ASIA, 2012 AND 2017 (%)</i>	89
CHAPTER 6 MARKETS BY DISEASE	92
<i>FIGURE 11 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, 2011 (%)</i>	92
ASTHMA DRUGS	92
MARKET REVENUES FOR ASTHMA DRUGS	93
MARKET SHARES, BY COMPANY	93
<i>FIGURE 12 MARKET SHARES OF LEADING MANUFACTURERS OF ASTHMA DRUGS, 2011 (%)</i>	93
NEW BRANDED ASTHMA DRUGS LAUNCHES	95
GENERIC DRUG LAUNCHES	95
<i>TABLE 38 PROJECTED GLOBAL MARKET FOR ASTHMA PRESCRIPTION DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	96
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	96
<i>FIGURE 13 MARKET SHARES OF LEADING MANUFACTURERS OF COPD DRUGS, 2011 (%)</i>	96
<i>TABLE 39 PROJECTED GLOBAL MARKET FOR COPD PRESCRIPTION DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	97
BRANDED COPD PRODUCT LAUNCHES	97
COMBINATION ASTHMA/COPD DRUGS	97
<i>TABLE 40 PROJECTED GLOBAL MARKET FOR COMBINATION ASTHMA/COPD DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	98
<i>FIGURE 14 MARKET SHARES OF LEADING MANUFACTURERS OF COMBINATION ASTHMA/COPD DRUGS, 2011 (%)</i>	98
<i>TABLE 41 PROJECTED GLOBAL MARKET FOR COMBINATION ASTHMA/COPD PRESCRIPTION DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	99
CHAPTER 7 EMERGING TRENDS AND PRODUCT PIPELINE REVIEW	101
THE "ASTHMA GENE"	101
ORAL DRUGS FOR ASTHMA	101
LEUKOTRIENE ORAL DRUGS	101
Masitinib	101
Oral Antifungal Treatment for Severe Asthma	101
DISEASE MODIFYING DRUGS	102
ASTHMA FORMULATIONS	102
COPD FORMULATIONS	102
BOEHRINGER INGELHEIM	102
FOREST LABORATORIES/AMIRALL SA	102
ELEVATION PHARMACEUTICALS	103
PEARL THERAPEUTICS	103
NOVEL BIOLOGICS	103
AMG 157	103
AMG 176	103
MEPOLIZUMAB	103
ULTRA LONG-ACTING MUSCARINIC ANTAGONISTS	103

TOPIC	PAGE NO.
ULTRA LONG-ACTING B ₂ AGONISTS (ULTRA-LABA)	104
LAMA AND LABA COMBINATION DRUGS	104
ANTI-INFLAMMATORY DRUGS	105
ANTI-PROTEASE	105
CHEMOKINE ANTAGONISTS	105
PPAR AGONISTS	105
ASTHMA/COPD DRUG DEVELOPMENT, BY COMPANY	105
<i>TABLE 42 ASTHMA/COPD PRODUCTS UNDER DEVELOPMENT, BY COMPANY, 2012</i>	106
ASTHMA DEVICES	108
CHAPTER 8 APPROVED DRUGS AND PATENT REVIEW	110
<i>TABLE 43 APPROVED DRUGS TO TREAT ASTHMA AND COPD, 1996 THROUGH 2011</i>	110
<i>TABLE 44 DRUGS SEEKING APPROVAL TO TREAT ASTHMA AND COPD 2012 THROUGH 2013</i>	111
PATENT REVIEW	111
<i>TABLE 45 ASTHMA/COPD TREATMENT PATENTS, BY COMPANY, DISEASE, PATENT NUMBER, YEAR FILED, 2011 THROUGH 2012</i>	112
<i>FIGURE 15 PERCENT OF REVIEWED PATENTS FOR ASTHMA, COPD, AND COMBINATION USE, JANUARY 2011 TO MAY 2012 (%)</i>	114
<i>TABLE 46 ASTHMA/COPD TREATMENT PATENTS, BY NUMBER, COMPANY, DESCRIPTION, AND DATE ISSUED, 2011 THROUGH 2012</i>	115
<i>TABLE 47 ASTHMA/COPD DRUG TREATMENT PATENTS ISSUED BETWEEN JANUARY 2011 AND MAY 2012, BY COMPANY</i>	123
<i>FIGURE 16 ASTHMA/COPD PATENTS, BY COUNTRY, 2011 THROUGH 2012 (%)</i>	125
CHAPTER 9 COMPANY PROFILES	127
ACTIENT PHARMACEUTICALS	127
AEROVANCE, INC.	127
ALMIRALL, S.A.	128
AMGEN INC.	128
APTAR PHARMA	129
ARGENTA DISCOVERY, LTD.	129
ASTRAZENECA	130
ASTRAZENECA PHARMACEUTICALS, LP	130
BOEHRINGER INGELHEIM GMBH	131
CHIESI FARMACEUTICI SPA	131
CORNERSTONE THERAPEUTICS	132
CYTOS BIOTECHNOLOGY AG	132
DEY PHARMA (MYLAN SPECIALTY L.P.)	133
FOREST LABORATORIES, INC.	133
GENENTECH, INC. (ROCHE)	133
GLAXO WELLCOME U.K., LTD.	134
GLAXOSMITHKLINE U.S.	134
MEDICINOVA	135
MEDICIS PHARMACEUTICAL	136
MEDIMMUNE	136
MERCK & CO., INC.	136
NOVARTIS PHARMA	137
NOVARTIS CORPORATION	137

TOPIC	PAGE NO.
NOVARTIS PHARMACEUTICALS CORPORATION	137
NYCOMED INTERNATIONAL (TAKEDA INTERNATIONAL)	138
OSIRIS THERAPEUTICS, INC.	139
PFIZER, INC.	139
SEPRACOR, INC. (SUNOVION)	140
SKYEPHARMA PLC	140
TEVA PHARMACEUTICAL INDUSTRIES, LTD.	141
TEVA PHARMACEUTICALS USA	141
THERAVANCE	142
RELOVAIR	142
LAMA/LABA (GSK573719/VILANTROL)	142
BIFUNCTIONAL MUSCARINIC ANTAGONIST-BETA2 AGONIST PROGRAM	142
INHALED LONG-ACTING MUSCARINIC ANTAGONIST (LAMA)	142
TOPIGEN PHARMACEUTICALS, INC. (PHARMAXIS LTD)	143
VECTURA GROUP PLC	143

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, THROUGH 2017 (\$ MILLIONS)	6
TABLE 1 MARKETED ASTHMA AND COPD DRUG CLASSES	20
TABLE 2 NET REVENUES FOR TOP SIX ASTHMA/COPD PRODUCT MANUFACTURERS, WITH PRODUCT(S), 2010 AND 2011 (\$ MILLIONS)	29
TABLE 3 NET REVENUES FOR TOP SPECIALTY ASTHMA/COPD MANUFACTURERS WITH PRODUCT(S), 2010 AND 2011 (\$ MILLIONS)	30
TABLE 4 NET REVENUES FOR SMALLER ASTHMA/COPD PRODUCT MANUFACTURER, WITH PRODUCT, 2010 AND 2011 (\$ MILLIONS)	30
TABLE 5 ACQUISITIONS AND MERGERS IN THE ASTHMA AND COPD MARKET, JANUARY 2008 TO JUNE 2012 (\$ MILLIONS)	31
TABLE 6 MAJOR ASTHMA/COPD DRUGS THAT LOSE PATENT PROTECTION BETWEEN 2008 AND 2024	35
TABLE 7 ASTHMA AND COPD SYMPTOM COMPARISONS	42
TABLE 8 CLASSIFICATION OF ASTHMA, BY SYMPTOMS	44
TABLE 9 ASTHMA AND COPD DRUG CLASSES	46
TABLE 10 CLASSIFICATION OF COPD AND ASTHMA	49
TABLE 11 PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN THE AMERICAS (%)	54
TABLE 12 PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN THE EMRA (%)	57
TABLE 13 PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN ASIA	61
TABLE 14 PROJECTED GLOBAL MARKET FOR ASTHMA AND COPD DRUG, BY DRUG CLASS, THROUGH 2017 (\$ MILLIONS)	63
TABLE 15 PROJECTED GLOBAL MARKET FOR BRONCHODILATORS, THROUGH 2017 (\$ MILLIONS)	65
TABLE 16 SHORT-ACTING BETA-2 AGONISTS, WITH APPROVAL AND PATENT EXPIRY DATES, 2011	67
TABLE 17 PROJECTED MARKET FOR SHORT-ACTING BETA-2 AGONIST BRONCHODILATORS, THROUGH 2017 (\$ MILLIONS)	68
TABLE 18 LONG-ACTING BETA-2 AGONISTS, 2011	69
TABLE 19 PROJECTED GLOBAL MARKET FOR LABA PRODUCTS, THROUGH 2017 (\$ MILLIONS)	70
TABLE 20 ANTICHOLINERGICS AND COMBINATION ANTICHOLINERGICS/SABA BY MANUFACTURER, 2011	71
TABLE 21 PROJECTED GLOBAL MARKET FOR ANTICHOLINERGICS, THROUGH 2017 (\$ MILLIONS)	72
TABLE 22 PROJECTED GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS BY TYPE, THROUGH 2017 (\$ MILLIONS)	74
TABLE 23 INHALED CORTICOSTEROIDS, 2011	75
TABLE 24 PROJECTED GLOBAL MARKET FOR INHALED CORTICOSTEROIDS, THROUGH 2017 (\$ MILLIONS)	77
TABLE 25 LEUKOTRIENE MODIFIERS, 2011	77
TABLE 26 PROJECTED GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, THROUGH 2017 (\$ MILLIONS)	78
TABLE 27 PROJECTED GLOBAL MARKET FOR PDE-4 DRUGS, THROUGH 2017 (\$ MILLIONS)	80
TABLE 28 PROJECTED GLOBAL MARKET FOR ASTHMA BIOLOGICAL DRUGS, THROUGH 2017 (\$ MILLIONS)	81
TABLE 29 COMBINATION ICS/LABA DRUGS, 2011	81
TABLE 30 PROJECTED GLOBAL MARKET FOR COMBINATION ICS/LABA DRUGS, THROUGH 2017 (\$ MILLIONS)	82

TABLE HEADING	PAGE NO.
TABLE 31 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS BY REGION, THROUGH 2017 (\$ MILLIONS)	85
TABLE 32 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE AMERICAS REGION, THROUGH 2017 (\$ MILLIONS)	85
TABLE 33 PROJECTED USE OF ASTHMA/COPD DRUGS IN THE AMERICAS' REGION, THROUGH 2017 (\$ MILLIONS)	86
TABLE 34 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE EMRA, THROUGH 2017 (\$ MILLIONS)	87
TABLE 35 PROJECTED USE OF ASTHMA/COPD DRUGS IN THE EMRA REGION, THROUGH 2017 (\$ MILLIONS)	87
TABLE 36 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE ASIAN REGION, THROUGH 2017 (\$ MILLIONS)	89
TABLE 37 PROJECTED USE OF ASTHMA/COPD DRUGS, BY REGION IN ASIA, THROUGH 2017 (\$ MILLIONS)	89
TABLE 38 PROJECTED GLOBAL MARKET FOR ASTHMA PRESCRIPTION DRUGS, THROUGH 2017 (\$ MILLIONS)	96
TABLE 39 PROJECTED GLOBAL MARKET FOR COPD PRESCRIPTION DRUGS, THROUGH 2017 (\$ MILLIONS)	97
TABLE 40 PROJECTED GLOBAL MARKET FOR COMBINATION ASTHMA/COPD DRUGS, THROUGH 2017 (\$ MILLIONS)	98
TABLE 41 PROJECTED GLOBAL MARKET FOR COMBINATION ASTHMA/COPD PRESCRIPTION DRUGS, THROUGH 2017 (\$ MILLIONS)	99
TABLE 42 ASTHMA/COPD PRODUCTS UNDER DEVELOPMENT, BY COMPANY, 2012	106
TABLE 43 APPROVED DRUGS TO TREAT ASTHMA AND COPD, 1996 THROUGH 2011	110
TABLE 44 DRUGS SEEKING APPROVAL TO TREAT ASTHMA AND COPD 2012 THROUGH 2013	111
TABLE 45 ASTHMA/COPD TREATMENT PATENTS, BY COMPANY, DISEASE, PATENT NUMBER, YEAR FILED, 2011 THROUGH 2012	112
TABLE 46 ASTHMA/COPD TREATMENT PATENTS, BY NUMBER, COMPANY, DESCRIPTION, AND DATE ISSUED, 2011 THROUGH 2012	115
TABLE 47 ASTHMA/COPD DRUG TREATMENT PATENTS ISSUED BETWEEN JANUARY 2011 AND MAY 2012, BY COMPANY	123

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY REGION, 2012 AND 2017 (%)	6
FIGURE 1 GLOBAL BRONCHODILATOR MARKET, BY TYPE, 2012 AND 2017 (%)	64
FIGURE 2 GLOBAL MARKET SHARE FOR BRONCHODILATORS BY COMPANY, 2011 (%)	65
FIGURE 3 MARKET SHARE FOR LABA BRONCHODILATORS BY COMPANY, 2011 (%)	70
FIGURE 4 MARKET SHARE OF ANTI-INFLAMMATORY DRUGS BY TYPE, 2012 AND 2017 (%)	72
FIGURE 5 MARKET SHARE OF LEADING MANUFACTURERS OF INHALED CORTICOSTEROIDS, 2011 (%)	76
FIGURE 6 GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, BY MANUFACTURER, 2012 AND 2017 (%)	79
FIGURE 7 MARKET SHARE OF MANUFACTURERS OF ICS/LABA, 2011 (%)	83
FIGURE 8 MARKET PERCENT OF ASTHMA/COPD DRUGS IN THE AMERICAS REGION, 2012 AND 2017 (%)	86
FIGURE 9 MARKET PERCENT OF ASTHMA/COPD DRUGS IN THE EMRA, 2012 AND 2017 (%)	88
FIGURE 10 MARKET PERCENTAGE OF ASTHMA/COPD DRUGS, BY REGION IN ASIA, 2012 AND 2017 (%)	89
FIGURE 11 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, 2011 (%)	92
FIGURE 12 MARKET SHARES OF LEADING MANUFACTURERS OF ASTHMA DRUGS, 2011 (%)	93
FIGURE 13 MARKET SHARES OF LEADING MANUFACTURERS OF COPD DRUGS, 2011 (%)	96
FIGURE 14 MARKET SHARES OF LEADING MANUFACTURERS OF COMBINATION ASTHMA/COPD DRUGS, 2011 (%)	98
FIGURE 15 PERCENT OF REVIEWED PATENTS FOR ASTHMA, COPD, AND COMBINATION USE, JANUARY 2011 TO MAY 2012 (%)	114
FIGURE 16 ASTHMA/COPD PATENTS, BY COUNTRY, 2011 THROUGH 2012 (%)	125